4upj: Difference between revisions

New page: left|200px<br /> <applet load="4upj" size="450" color="white" frame="true" align="right" spinBox="true" caption="4upj, resolution 1.9Å" /> '''HUMAN IMMUNODEFICIEN...
 
No edit summary
Line 1: Line 1:
[[Image:4upj.gif|left|200px]]<br />
[[Image:4upj.gif|left|200px]]<br /><applet load="4upj" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="4upj" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="4upj, resolution 1.9&Aring;" />
caption="4upj, resolution 1.9&Aring;" />
'''HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 PROTEASE MUTANT WITH LYS 57 REPLACED BY LEU (K57L) COMPLEX WITH U097410 [4-HYDROXY-3-[1-[3-[[[[(TERT-BUTYLOXYCARBONYL) AMINOMETHYL]CARBONYL]AMINO]PHENYL]PROPYL]COUMARIN'''<br />
'''HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 PROTEASE MUTANT WITH LYS 57 REPLACED BY LEU (K57L) COMPLEX WITH U097410 [4-HYDROXY-3-[1-[3-[[[[(TERT-BUTYLOXYCARBONYL) AMINOMETHYL]CARBONYL]AMINO]PHENYL]PROPYL]COUMARIN'''<br />


==Overview==
==Overview==
The low oral bioavailability and rapid biliary excretion of, peptide-derived HIV protease inhibitors have limited their utility as, potential therapeutic agents. Our broad screening program to discover, nonpeptidic HIV protease inhibitors had previously identified compound II, (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of, HIV protease complexes containing the peptide-derived inhibitor I, (1-(naphthoxyacetyl)-L-histidyl-5(S)-amino-6-cyclohexyl-3, (R),4(R)-dihydroxy-2(R)-isopropylhexanoyl-L-isoleucine, N-(2-pyridylmethyl)amide) and nonpeptidic inhibitors, such as, phenprocoumon (compound II), provided a rational basis for the, structure-based design of more active analogues. This investigation, reports on the important finding of a carboxamide functionally, appropriately added to the 4-hydroxycoumarin and the 4-hydroxy-2-pyrone, templates which resulted in a new promising series of nonpeptidic HIV, protease inhibitors with improved enzyme-binding affinity. The most active, diastereomer of the carboxamide-containing compound XXIV inhibited HIV-1, protease with a K(i) value of 0.0014 muM. This research provides a new, design direction for the discovery of more potent HIV protease inhibitors, as potential therapeutic agents for the treatment of HIV infection.
The low oral bioavailability and rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as potential therapeutic agents. Our broad screening program to discover nonpeptidic HIV protease inhibitors had previously identified compound II (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of HIV protease complexes containing the peptide-derived inhibitor I (1-(naphthoxyacetyl)-L-histidyl-5(S)-amino-6-cyclohexyl-3 (R),4(R)-dihydroxy-2(R)-isopropylhexanoyl-L-isoleucine N-(2-pyridylmethyl)amide) and nonpeptidic inhibitors, such as phenprocoumon (compound II), provided a rational basis for the structure-based design of more active analogues. This investigation reports on the important finding of a carboxamide functionally appropriately added to the 4-hydroxycoumarin and the 4-hydroxy-2-pyrone templates which resulted in a new promising series of nonpeptidic HIV protease inhibitors with improved enzyme-binding affinity. The most active diastereomer of the carboxamide-containing compound XXIV inhibited HIV-1 protease with a K(i) value of 0.0014 muM. This research provides a new design direction for the discovery of more potent HIV protease inhibitors as potential therapeutic agents for the treatment of HIV infection.


==About this Structure==
==About this Structure==
4UPJ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with U04 as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=4UPJ OCA].  
4UPJ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with <scene name='pdbligand=U04:'>U04</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UPJ OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Human immunodeficiency virus 1]]
[[Category: Human immunodeficiency virus 1]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Janakiraman, M.N.]]
[[Category: Janakiraman, M N.]]
[[Category: Mulichak, A.M.]]
[[Category: Mulichak, A M.]]
[[Category: Watenpaugh, K.D.]]
[[Category: Watenpaugh, K D.]]
[[Category: U04]]
[[Category: U04]]
[[Category: hydrolase (acid protease)]]
[[Category: hydrolase (acid protease)]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov  8 14:59:06 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 19:14:38 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA